

November 21, 2025
Fuji Pharma Co., Ltd.

**Notice of Additional Approval for the indication of Nextstellis™
by OLIC (Thailand) Limited**

Fuji Pharma Co., Ltd. (“Fuji”) is pleased to announce that Fuji’s group company, OLIC (Thailand) Limited has received additional approval of the indication “dysmenorrhea” for Nextstellis™ in Thailand, effective November 10, 2025.

Nextstellis™ is a noteworthy product, as it represents the first pharmaceutical product from the Fuji Pharma group that has been marketed. This combination tablet contains drospirenone (DRSP) and natural estrogen Estetrol (E₄), and has the same ingredients as the Alyssa® combination tablets marketed in Japan. Nextstellis™ has been marketed in Thailand since April 2023 for the indication of “contraception”

Dysmenorrhea¹ commonly referred to as menstrual pain, manifests as lower abdominal pain, back pain and may encompass various additional symptoms, it encompasses various other symptoms. A survey² conducted among female university students in Thailand indicate a prevalence rate of dysmenorrhea at approximately 85%. Of these, over 60% reported “reduced concentration during classes,” and in severe cases, about 80% reported “missed classes” due to their symptoms. Thus, dysmenorrhea is therefore recognized as a significant public health concern in Thailand.

Through this new approval, we anticipate that Nextstellis™ provide a new therapeutic option not only for contraception but also for the management of dysmenorrhea. We believe that Nextstellis™ will help create an environment in which women can fully engage in their daily activities, academic pursuits and work life.

Fuji Pharma Group will continue to creating new value in women’s healthcare and contributing to society where everyone can enjoy well-being.

For further information about [Notice of Application for Additional Approval of indication of Nextstellis™ by OLIC \(Thailand\) Limited](#).

Note

The financial forecasts and other projections provided in this release are based on information available at the time of its compilation and it therefore contains an element of uncertainty and potential risks. Actual results may differ significantly from these forecasts for a number of reasons. It should also be noted that the views and/or facts presented here may be altered or deleted without prior notification. Information in this release about pharmaceuticals (including items in the pipeline) is not provided for the purpose of marketing or advertising or of supplying medical advice.

For further information, contact

Fuji Pharma Co., Ltd.

Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division

fsks@fujipharma.jp

¹ Fuji Pharma Co., Ltd. Corporate Website For the General Public and Patients “What is Dysmenorrhea?”
<https://www.fujipharma.jp/patients/dysmenorrhea/about/#m03>

² The Journal of the Medical Association of Thailand (J Med Assoc Thai) Vol. 87 Suppl. 3 2004